Corporate narration: Pharmaceutical. English
Description
Vocal Characteristics
Language
EnglishVoice Age
Middle Aged (35-54)Accents
British (General)Transcript
Note: Transcripts are generated using speech recognition software and may contain errors.
Systemic light chain. A amyloidosis is a rare and incurable bone marrow disorder that comes with debilitating symptoms including serious organ damage. The decision by the National Institute for Health and Care Excellence not to recommend Daat Touma in combination with Bortezomib cyclophosphoricum Meson within its marketing authorization means that there remain no license treatment options available routinely via the NHS for those patients living with this life threatening disease in England and Wales. The outcome is especially disappointing given that the Scottish Medicines Consortium accepted Daratumumab in combination with B CD for use in the full licensed population. Earlier this year, the treatment has also been made available to NHS patients in northern Ireland. The nice decision raises concern about the current assessment framework for rare disease therapies in England and Wales and highlights potential discrepancies in the methodology used by the different health assessment bodies in England, Scotland and Northern Ireland. Jansen believes that existing evaluation methods should be reformed to ensure equitable access of new medicines for rare diseases across the UK, especially in areas of such high unmet need.